Advertisement

Use of Nonlinear Mixed Effects Modelling in the Development of in Vitro-in Vivo Correlations

  • Sian Bigora
  • Deborah Piscitelli
  • James Dowell
  • Jackie Butler
  • Colm Farrell
  • John Devane
  • David Young
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 423)

Abstract

The variability associated with the estimation of the pharmacokinetic and pharmacodynamic parameters of a population has traditionally been described using simple statistical terms such as the mean and standard deviation. Other sources of variability exist within the population, such as the quantitative relationship of the parameter to individual physiology (such as weight, age, kidney function), the magnitude of the intersubject variability across the population and the magnitude of the residual deviations between the predicted and observed drug concentrations within a subject1,2.

Keywords

Cumulative Amount Akaike Information Criterion Intersubject Variability Nonlinear Mixed Effect Nonlinear Mixed Effect Modelling 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sheiner LB, Grasela TH. An introduction to mixed effects modeling: concepts, definitions and justification. J Pharmacokinetic Biopharm 1991; 19: 11S–23S.CrossRefGoogle Scholar
  2. 2.
    Sheiner LB. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 1984;15: 153–71.PubMedCrossRefGoogle Scholar
  3. 3.
    Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 1981;9: 635–651.PubMedCrossRefGoogle Scholar
  4. 4.
    Beal SL, Sheiner LB. Population pharmacokinetic data and parameter estimation based on their first two statistical moments. Drug Metab Rev 1984;15: 173–93.PubMedCrossRefGoogle Scholar
  5. 5.
    Beal SL and Sheiner LB. NONMEM Users guides, NONMEM Project Group, UCSF, San Francisco, CA, 1992.Google Scholar
  6. 6.
    In vitro-in vivo correlations. Pharmacopeial Forum USP 1993;19:5374-9.Google Scholar
  7. 7.
    ‘Draft guidance for industry: modified release solid dosage forms; scale-up and post-approval changes: chemistry, manufacturing and controls, in vitro dissolution testing and in vivo bioequivalence documentation. U.S. Department of Health and Human Services, Food and Drug Administration, July 1996.Google Scholar
  8. 8.
    Leeson LJ. In vitro/in vivo correlations. Drug Info J 1995;29: 903–15.CrossRefGoogle Scholar
  9. 9.
    Hussein Z, Freidman M. Release and absorption characteristics of novel theophylline sustained-release formulations: in vitro-in vivo correlation. Pharm Res 1990;7: 1167–71.PubMedCrossRefGoogle Scholar
  10. 10.
    Hyashi T, Ogura T, Takagishi Y. New evaluation method for in vitro/in vivo correlation of enteric coated multiple unit dosage forms. Pharm Res 1995;12: 1333–7.CrossRefGoogle Scholar
  11. 11.
    Gillespie WR, Veng-Pedersen P. A polyexponential deconvolution method. Evaluation of the “gastrointestinal bioavailability” and mean in vivo dissolution time of some ibuprofen dosage forms. J Pharmacokinet Biopharm 1985;13: 289–307.Google Scholar
  12. 12.
    Gillespie WR. PCDCON: Deconvolution for pharmacokinetic applications. University of Texas at Austin, Austin TX. 1992Google Scholar
  13. 13.
    ADAPT II. D’Argenio D. Biomedical Simulations Resource, USC, CA.Google Scholar

Copyright information

© Plenum Press, New York 1997

Authors and Affiliations

  • Sian Bigora
    • 1
  • Deborah Piscitelli
    • 1
  • James Dowell
    • 1
  • Jackie Butler
    • 2
  • Colm Farrell
    • 2
  • John Devane
    • 2
  • David Young
    • 1
  1. 1.IVIVR Cooperative Working Group Pharmacokinetics-Biopharmaceutics LaboratoryUniversity of Maryland at BaltimoreBaltimoreUSA
  2. 2.IVIVR Cooperative Working GroupElan Corporation PLCAthloneIreland

Personalised recommendations